Dr. Li Guochun: In the next 3-5 years, China will have a pharmaceutical company with a market value of hundreds of billions of dollars.

Guide: China's biopharmaceutical industry is in a critical period of quality improvement, how to balance capital and innovation is the key issue he has ponderedhe says he's a veteran of the pharmaceutical industry and a newcomer to the investment businessChina's biopharmaceutical industry is in a critical period of quality improvement, how to balance capital and innovation is the key issue he has ponderedHe firmly believes that in the next three to five years, China will have a market value of hundreds of billions of dollars of pharmaceutical companies! He is a senior partner at Yuansheng Ventures: DrLi Guochuna veteran of medicine, investin in newbefore joining Yuansheng Ventures, DrLi Guochun has been in charge of early drug research and development work in Novartis, an internationally renowned biopharmaceutical company, for more than 10 yearsAfter returning to China, he served as Deputy General Manager of Harbin Yuheng Pharmaceutical Co., LtdIn April, DrLi quit his job at Yuheng Pharmaceuticals and made an important decision in the cross-border fund investment industryIn an exclusive interview with Biodiscovery, DrLi Guochun admitted that the four years of Harbin Yuheng Pharmaceuticals were also the four years of China's drug reformHe has witnessed the change sours of China's biopharmaceutical industry from an early focus on basic process development to a certain scale of innovation todayAs a pharmaceutical veteran, DrLi Guochun is well aware of the difficulties and bottlenecks in the process of pharmaceutical research and development, and his original intention in turning around the border is to make full use of his extensive experience in multinational enterprises and listed companies to help more early entrepreneurs, and make Innovation in China's biopharmaceutical industry bigger and strongercross-border shift requires not only courage, but also a shift in focus Dr Li Guochun told Biodiscovery that his research and development efforts had previously tended to focus on targeted therapy, and that he had to learn how to industrialize when moving to the pharmaceutical industry, while now investing in funds focused more on finding differentiated innovations "In the face of the changing tide of China's pharmaceutical industry, both entrepreneurs and investment institutions need to make a change In the past, we have invested more on the star team, focusing on the beginning of the project Li Guochun said He thinks a good concept needs to be considered at both ends to build a biomedical ecosystem Dr Li Guochun specifically said that from the perspective of entrepreneurs at one end, after experiencing the chaos of early pile-up research, we should relax our horizons to see the needs of china's clinical diversification today, forming differentiated competition, rather than talking about the so-called hot spots Similarly, for investment institutions, each fund has its own characteristics The original idea of looking for star team investment needs to change, and now the investment trend is more in the light of the industry trends on the basis of differentiated investment In this process, it is important to communicate with entrepreneurs, investors and professionals to share resources to solve the pain points of the entrepreneurial team, but also to help investors see the later interaction of resources, and thus create the concept of the pharmaceutical ecosystem from the other end, Dr Li Guochun said he would focus on the back In the past five years, for a variety of reasons, many entrepreneurs are more concerned about how to promote products to the clinic, which is also the reason for the emergence of many productpiles With the change of national policy, the state has strengthened the supervision of the biopharmaceutical industry, while also allowing early clinical products from abroad to enter the country, which is a greater challenge for entrepreneurs Dr Li Guochun believes it is particularly important for gene investors to focus on changes in the industry's back end Among them, Dr Li Guochun believes that investment institutions should play a good role as a bridge between the early projects and the changes in the industry behind them looking at China's venture capital industry, it has slowly learned how to walk since its former infancy In Dr Li Guochun's view, today's investment institutions are looking for professional GPs in a relatively market-oriented way to promote the development of the entire biopharmaceutical industry "Yuansheng Ventures also wants to do better in the new situation, combining the genes and characteristics that it has already had to transform, " he said Yuansheng Ventures began with BioBAY and is also rooted in BioBAY, and for BioBAY it is also hoped that Yuansheng will expand outwards, from BioBAY to the Yangtze River Delta, from the Yangtze River Delta to the whole of China, and even slowly with the world has more of a connection "
of course, balancing risk and return is something every investor needs to consider As an investment institution, Yuansheng Ventures focuses on venture capital investment in early biopharmaceutical companies In this marathon arena of investing in entrepreneurship, Yuansheng Ventures has been moving wisely For the investment of early projects, Yuansheng Ventures will actively participate in of course, the investment enterprise's clinical, production, market and other elements have strict requirements Dr Li hopes to build an ecosystem in the investment sector to reduce the risk of investment and better serve entrepreneurs through linkages with each other take the path of biomedicine with Chinese characteristics
from the historical development, China's biomedicine has developed to a certain node Neither the clinician nor the entrepreneur should stay on the surface of the matter, but focus on the specific things The Sino-US trade war has forced China's biopharmaceutical companies to innovate and develop, which, in Dr Li's view, is a good thing in a sense Similar to the original IT industry, the biopharmaceutical industry can only adapt to China's national conditions, combined with Chinese characteristics, in the new era to produce something new Moreover, the path of biomedicine with Chinese characteristics has a certain demonstration effect on the third world to some extent As a big country, China should also have its own responsibilities and responsibilities in the field of biomedicine since the opening of the board, the biopharmaceutical sector has risen amazingly, can be described as a unique show Dr Li Guochun believes that the company's board is a good attempt to develop China's biopharmaceutical industry For both entrepreneurs and investment institutions, the board opens up a larger vision, just as medieval Europeans discovered the new continent of the Americas The development factors of the biopharmaceutical industry, such as research and development, technology and capital, will be opened up, which is conducive to the development of China's biopharmaceutical ecosystem on the other hand, the listing of the company also presents some challenges Dr Li Guochun thought, we will find that many of the biopharmaceutical enterprises in the branch board is a new three-plate turnboard, which shows that the biopharmaceutical this piece is actually a lake, so it is caused by the new policy, there is a very large amount of the process of release Of course, he also has high expectations for the company: the next three to five years will be able to work with practitioners across the industry, using this opportunity to make China's biopharmaceutical industry a better ecological construction concluded at the end of the interview, Dr Li Guochun predicted that in the next few years China will have a hundred billion dollars market value of a biopharmaceutical company This will be a benchmark, the enterprise to achieve this level, indicating that it has a mature development in strategic layout, market competition, enterprise management and so on Such a business is not necessarily a kind of proficiency, but in the industry there must be hard nuclear technology He stressed that China's pharmaceutical companies, whether start-up small companies, or the steady development of large companies should have the spirit of artisans, a project to do deep, pioneering and innovative This will hopefully become the next "Huawei" in the biopharmaceutical industry .